SMAD4 is required for development of maximal endotoxin tolerance.
Initial exposure of monocytes/macrophages to LPS induces hyporesponsiveness to a second challenge with LPS, a phenomenon termed LPS tolerance. Molecular mechanisms responsible for endotoxin tolerance are not well defined. We and others have shown that IL-1R-associated kinase (IRAK)-M and SHIP-1 proteins, negative regulators of TLR4 signaling, increase in tolerized cells. TGF-beta1, an anti-inflammatory cytokine, is upregulated following LPS stimulation, mediating its effect through SMAD family proteins. Using a monocytic cell line, THP1, we show that LPS activates endogenous SMAD4, inducing its migration into the nucleus and increasing its expression. Secondary challenge with high dose LPS following initial low-dose LPS exposure does not increase IRAK-M or SHIP1 protein expression in small hairpin (sh)SMAD4 THP-1 cells compared with control shLUC THP1 cells. TNF-alpha concentrations in culture supernatants after second LPS challenge are higher in shSMAD4 THP-1 cells than shLUC THP1 cells, indicating failure to induce maximal tolerance in absence of SMAD4 signaling. Identical results are seen in primary murine macrophages and mouse embryonic fibroblasts, demonstrating the biological significance of our findings. TGF-beta1 treatment does not increase IRAK-M or SHIP1 protein expression in shSMAD4 THP-1 cells, whereas it does so in shLUC THP1 cells, indicating that TGF-beta1 regulates IRAK-M and SHIP1 expression through a SMAD4-dependent pathway. Knockdown of endogenous SHIP1 by shSHIP1 RNA decreases native and inducible IRAK-M protein expression and prevents development of endotoxin tolerance in THP1 cells. We conclude that in THP-1 cells and primary murine cells, SMAD4 signaling is required for maximal induction of endotoxin tolerance via modulation of SHIP1 and IRAK-M.
Pan
Hongjie
H
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Ding
Enyu
E
Hu
Mai
M
Lagoo
Anand S
AS
Datto
Michael B
MB
Lagoo-Deenadayalan
Sandhya A
SA
D000818:Animals; D002460:Cell Line; D045744:Cell Line, Tumor; D004306:Dose-Response Relationship, Immunologic; D015536:Down-Regulation / Q000235:genetics / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance / Q000235:genetics; D000072181:Inositol Polyphosphate 5-Phosphatases; D053592:Interleukin-1 Receptor-Associated Kinases / Q000378:metabolism / Q000502:physiology; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors / Q000633:toxicity*; D051379:Mice; D008810:Mice, Inbred C57BL; D000072183:Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; D010744:Phosphoric Monoester Hydrolases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology; D034741:RNA, Small Interfering / Q000494:pharmacology; D015398:Signal Transduction / Q000235:genetics / Q000276:immunology; D051901:Smad4 Protein / Q000502:physiology*; D016212:Transforming Growth Factor beta / Q000502:physiology
D008070:Lipopolysaccharides; D034741:RNA, Small Interfering; C497796:SMAD4 protein, human; D051901:Smad4 Protein; C490810:Smad4 protein, mouse; D016212:Transforming Growth Factor beta; C507771:IRAK3 protein, human; D053592:Interleukin-1 Receptor-Associated Kinases; C507772:Irak3 protein, mouse; D010744:Phosphoric Monoester Hydrolases; D000072181:Inositol Polyphosphate 5-Phosphatases; C000606430:INPP5D protein, human; C000606433:Inpp5d protein, mouse; D000072183:Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases
Oncogene. 2005 Aug 29;24(37):5701-12
16123803
J Exp Med. 1995 May 1;181(5):1887-92
7722463
Genes Dev. 2005 Nov 15;19(22):2668-81
16260493
Circ Res. 2000 Jun 9;86(11):1122-8
10850962
FEBS Lett. 2000 Feb 11;467(2-3):160-4
10675530
Annu Rev Immunol. 1998;16:137-61
9597127
Immunol Lett. 2005 Nov 15;101(2):217-22
16054705
Immunity. 2004 Aug;21(2):227-39
15308103
Cell. 2002 Jul 26;110(2):191-202
12150927
J Immunol. 2004 Mar 15;172(6):3814-21
15004187
Crit Care. 2006;10(5):233
17044947
Trends Immunol. 2003 Jul;24(7):358-63
12860525
J Immunol. 2004 Jul 15;173(2):962-8
15240683
Immunity. 2002 Nov;17(5):677-87
12433373
J Cell Physiol. 1989 Aug;140(2):396-402
2745570
Ann Intern Med. 1996 Sep 15;125(6):520-1
8779480
J Endotoxin Res. 2003;9(2):101-7
12803883
Biochem Biophys Res Commun. 2003 Nov 14;311(2):465-72
14592437
Nature. 2001 Jul 19;412(6844):346-51
11460167
Proc Natl Acad Sci U S A. 1987 Sep;84(17):6020-4
2888109
Mol Cells. 2002 Aug 31;14(1):35-42
12243350
J Immunol. 2008 Mar 15;180(6):4218-26
18322234
Blood. 2005 Jun 15;105(12):4685-92
15701712
Nature. 1999 Sep 2;401(6748):82-5
10485710
J Biol Chem. 2006 Jun 16;281(24):16473-81
16613850
Science. 1995 Dec 22;270(5244):2008-11
8533096
Cell. 2004 Jun 25;117(7):927-39
15210113
Annu Rev Immunol. 1995;13:437-57
7542010
Eur J Immunol. 2003 Mar;33(3):597-605
12616480
J Biol Chem. 2005 Feb 18;280(7):5491-5
15623538
J Immunol. 2009 May 15;182(10):6444-51
19414798
Crit Care Med. 2002 Jan;30(1 Supp):S64-S73
11891406
J Leukoc Biol. 1998 Jan;63(1):31-9
9469470
Trends Biochem Sci. 2004 May;29(5):265-73
15130563
Cell. 2000 Oct 13;103(2):351-61
11057907
Blood. 1992 Apr 1;79(7):1679-85
1532754